Effect of Novel Glucagon Receptor Antagonist REMD-477 on Glucose and Adipocyte Metabolism in T2DM

  • STATUS
    Recruiting
  • End date
    Nov 26, 2024
  • participants needed
    24
  • sponsor
    The University of Texas Health Science Center at San Antonio
Updated on 29 December 2021
insulin
metformin
glucagon
hemoglobin a1c
antidiabetic agents

Summary

With REMD's glucagon receptor antagonist, the study team propose to provide a comprehensive examination of the effect of elevated plasma glucagon concentrations in Type 2 Diabetes Mellitus (T2D) patients on:

(i) glucose tolerance; (ii) insulin sensitivity in liver, muscle, and adipocytes; (iii) beta cell function; (iv) adipocyte inflammation.

Description

Subjects with T2DM inadequately controlled on current medications will participate in a glucose tolerance test, euglycemic insulin clamp combined with 3-3H-glucose and 14-C glycerol infusion, adipose tissue biopsy, before and 12 weeks after treatment with REMD 477 or placebo.

Details
Condition Type 2 Diabetes, Glucose Tolerance Impaired, Insulin Sensitivity
Treatment REMD-477, Placebo Subcutaneous Injection
Clinical Study IdentifierNCT05093517
SponsorThe University of Texas Health Science Center at San Antonio
Last Modified on29 December 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Type 2 diabetic subjects, males/females
age = 18-70 years
BMI = 25-40 kg/m2
HbA1c = 7.5-10.0%
Type 2 Diabetics who are drug naïve or treated with metformin, sulfonylureas, SGLT-2 inhibitors or any combination thereof
Subjects must be on a stable dose of antidiabetic medications for at least 3 months prior to study
Patients must be able to communicate meaningfully with the investigator and must be legally competent to provide written informed consent
Female patients must be non-lactating and must either be at least two years post-menopausal, or be using adequate contraceptive precautions (i.e. oral contraceptives, approved hormonal implant, intrauterine device, diaphragm with spermicide, condom with spermicide), or be surgically sterilized (i.e. bilateral tubal ligation, bilateral oophorectomy). Female patients who have undergone a hysterectomy are eligible for participation in the study. Female patients (except for those patients who have undergone a hysterectomy or a bilateral oophorectomy) are eligible only if they have a negative pregnancy test throughout the study period

Exclusion Criteria

Subjects with a personal or family history of pancreatic neuroendocrine tumors or multiple endocrine neoplasia, due to the potential increased of pancreatic alpha cell carcinogenicity associated with glucagon receptor antagonists
Subjects with a contraindication to MRI including artificial heart valves or pacemakers
Patients with a known sensitivity to humanized antibodies
Subjects treated with GLP-1 RAs or insulin are excluded
Subjects treated with a non-antidiabetic medication that may impact insulin sensitivity, such as systemic steroids, or lipase inhibitors (orlistat, Alli or Xenical)
Hematocrit < 34 vol%
Serum creatinine > 1.8 mg/dl
AST (SGOT) > 2 times upper limit of normal
ALT (SGPT) > 2 times upper limit of normal
Any major organ system disease as identified by medical history, physical exam, and screening blood tests, EKG
Subjects who cannot give written, voluntary consent
Subjects with a major psychiatric disturbance
Only subjects whose body weight has been stable (±3-4 pounds) over the three months prior to study will be included
Patients must not have type 1 diabetes
Patients must not have a fasting plasma glucose of greater than 270 mg/dl or HbA1c > 10.0%
Patients must not have received a thiazolidinedione, GLP-1 agonist, or insulin for more than one week during the year prior to randomization
Patients with a history of clinically significant heart disease (New York Heart Classification greater than class 2; more than non-specific ST-T wave changes on the EKG), peripheral vascular disease (history of claudication), or pulmonary disease (dyspnea on exertion of one flight or less; abnormal breath sounds on auscultation) will not be studied
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note